Chen Schor is President and CEO of Adicet Bio, a leader in the field of gamma-delta CAR T cell therapies for the treatment of cancer. With more than 25 years of global biopharmaceutical leadership experience, he has led several biotech companies across all stages, from formation, to early-stage discovery, to publicly traded multi-product companies with significant industry partnerships.
Mr. Schor has led strategic transactions valued at over $8 billion with companies such as GSK, Amgen, Pfizer, Merck KGaA and equity financing totaling more than $500 million. He led the turnaround of Synta Pharmaceuticals and its reverse merger with Madrigal Pharmaceuticals (Nasdaq: MDGL), served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals and in leadership positions at several emerging private and public companies. Mr. Schor was a Partner at Yozma Venture Capital where he led the foundation and growth of multiple therapeutic companies from inception to significant commercial success and exit.
He is a board member with the Alliance for Cancer Gene Therapy, a non-for-profit organization committed to advancing new cancer cell and gene therapies, Chairman of the Board of Carbon Biosciences, a gene therapy company, and board member with Karyopharm Therapeutics, a commercial stage oncology company.
Mr. Schor holds a MBA, a B.A. in Biology, a B.A. in Economics and is a Certified Public Accountant (CPA).
How old is Chen Schor BA?
Mr. BA is currently 52 years old. There are 5 older executives and no younger executives at Adicet Bio. The oldest executive at Adicet Bio is Dr. Aya Jakobovits Ph.D., Founder & Independent Director, who is 69 years old. Learn More on Chen Schor BA's age.
How do I contact Chen Schor BA?
Has Chen Schor BA been buying or selling shares of Adicet Bio?
Who are Adicet Bio's active insiders?
